-
Mashup Score: 2Jewish Women and BRCA Gene Mutations | Bring Your Brave | CDC - 1 year(s) ago
Ashkenazi Jewish women are 10 times more likely to have a BRCA1 or BRCA2 gene mutation than women in the general United States population.
Source: www.cdc.govCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 3BRCA Gene Mutations: Cancer Risk and Genetic Testing Fact Sheet - 1 year(s) ago
A fact sheet about the BRCA1 and BRCA2 genes, what to do if a person tests positive for alterations in one of these genes, and consequences of genetic testing.
Source: National Cancer InstituteCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
š§µ(3/3) Anyone who is concerned about the possibility that they may have a harmful variant in the BRCA1 or BRCA2 gene should discuss their concerns with their health care provider or a genetic counselor. https://t.co/UvY0mj8TpI #BRCA #BreastCancer #BringYourBrave
-
-
Mashup Score: 0Heterogeneity and Clonal Evolution of Acquired PARP Inhibitor Resistance in TP53- and BRCA1-Deficient Cells - 1 year(s) ago
This study shows that BRCA1-deficient cells can give rise to multiple genomically and functionally heterogenous PARPi-resistant clones, which are associated with various vulnerabilities that can be targeted in a mechanism-specific manner.
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet-
At the #AACR23 educational session on Exploiting the DNA Damage Response in Novel Therapy Approaches? Check out this recent article from session chair Alan DāAndrea on PARP inhibitor resistance in p53 and #BRCA deficient cancerā https://t.co/NJSBI3FSVw https://t.co/MNtCIC80QX
-
-
Mashup Score: 3
Bristol Myers Squibb, GlaxoSmithKline, the Basser Center Young Leadership Council, The Konner Foundation, The Pearl and Philip Basser Innovation Research Award, the Anonymous Foundation, and the US National Institutes of Health.
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
@BrunoBockorny @TumorBoardTues @OncoAlert @OncBrothers @Aiims1742 @PancPathologist @PanCAN @PancreaticCanUK @drallysonocean @ShaalanBeg @VivekSubbiah @BenWestphalen @MPishvaian @marklewismd @UmutDisel @Dr_R_Kurzrock @PeterHoseinMD @JAMAOnc š”The #immunotherapy & #BRCA story appears to be more CTLA4āļø>>>PD1/PDL1āļø. BRCA1/2/PALB2: in the niraparib plus ipilimumab group, PFS 10Ā·4 months (1Ā·5ā19Ā·2) OS was 38Ā·0 months (not estimable). @KReissMDās data @OncoAlert šš¾ A PARPāPD1 B PARPāCTLA4 https://t.co/DT38mRJgVt https://t.co/rKW03oaUVi
-
-
Mashup Score: 5
The Institute of Cancer Research, London, has hailed the ālife-changingā decision by NICE to recommend that the targeted drug olaparib can be used for NHS patients with both early-stage breast cancer and prostate cancer.
Source: www.icr.ac.ukCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @ICR_London: Last week, the drug, olaparib was recommended for NHS patients with advanced #ProstateCancer: https://t.co/PkrtplEZP6 Theā¦
-
Last week, the drug, olaparib was recommended for NHS patients with advanced #ProstateCancer: https://t.co/PkrtplEZP6 The ICR and @royalmarsdenNHS led clinical trials that showed that olaparib was effective for patients with a range of cancers with #BRCA 1/2 mutations ā¬ļø https://t.co/Ux2WUs6HCL
-
-
Mashup Score: 2
The Institute of Cancer Research, London, has hailed the ālife-changingā decision by NICE to recommend that the targeted drug olaparib can be used for NHS patients with both early-stage breast cancer and prostate cancer.
Source: www.icr.ac.ukCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Professor Chris Lord (@IcrLordLab) was part of the team that showed that PARP inhibitors, such as olaparib, can selectively target cells with #BRCA 1/2 mutations. Read about olaparib's recommendation for NHS patients with breast and #ProstateCancer: https://t.co/PkrtplErZy https://t.co/PObbxsehfO
-
-
Mashup Score: 1Nationwide Trends and Determinants of Germline BRCA1/2 Testing in Patients With Breast and Ovarian Cancer - 1 year(s) ago
Background: Germline genetic testing (GT) for BRCA1/2 is instrumental in identifying patients with breast and ovarian cancers who are eligible for PARP inhibitors (PARPi). Little is known about recent trends and determinants of GT since PARPi were approved for these patients. Patients and Methods: We performed a retrospective cohort study of patients in a nationwide electronic health record…
Source: JNCCNCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Nationwide Trends and Determinants of Germline #BRCA 1/2 Testing in Patients With #BreastCancer and #OvarianCancer: https://t.co/ua8HcHNC3o #GynCSM #BCSM #genetictesting #hsronc by @KelseyLauMin @annemckn1 @klnathanson & Susan Domchek, MD @BasserBRCA https://t.co/T4GHZw4Btm
-
-
Mashup Score: 2
The Institute of Cancer Research, London, has hailed the ālife-changingā decision by NICE to recommend that the targeted drug olaparib can be used for NHS patients with both early-stage breast cancer and prostate cancer.
Source: www.icr.ac.ukCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Men in England and Wales with advanced, incurable #ProstateCancer who have #BRCA 1/2 mutations in their tumours will have access to olaparib on the NHS ā delaying progression of their disease and keeping them alive for longer. Read more: https://t.co/PkrtplErZy https://t.co/oFX8svUqpT
-
-
Mashup Score: 11
As the first clinical trial of the drug novobiocin is about to open for patients with cancers carrying BRCA gene mutations, new research at Dana-Farber Cancer Institute shows the drug poses a double threat to tumor cells.
Source: medicalxpress.comCategories: General Medicine News, Latest HeadlinesTweet-
Novobiocin attacks #BRCA-mutated cancer cells from within and without, study shows @danafarber @NatureComms https://t.co/GxpTUPyeXa
-
-
Mashup Score: 0
DNA damage in normal breast epithelium of BRCA mutation carriers is enhanced by obesity.
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Read this week's Cancer Discovery #ResearchWatch: Obesity Increases Breast Epithelium DNA Damage in #BRCA Mutation Carriers, a summary of the paper by @PriyaBhardwaj, @BrownLab_WCM et al. https://t.co/xB27q9lqve @WeillCornell https://t.co/ID1pytH4zs
-
š§µ(2/3) Ashkenazi Jews are more likely than most other groups to carry inherited genetic changes in BRCA1 and BRCA2 that increase their risk of breast and several other cancers. https://t.co/5tYgkWVgHm. #BRCA #BCSM #JewishAmericanHeritageMonth #BringYourBrave https://t.co/iTu9V7aGvd